Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDs).
New York-based Stemline won Food and Drug Administration approval in December 2018 for Elzonris, a drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN, an extremely rare but aggressive form of leukemia.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
A biopharmaceutical company developing cancer therapies that zero in on cancer stem cells to treat brain cancer and acute myeloid leukemia is seeking to raise $50 million in an initial public offering. Cancer stem cells are viewed as highly malignant “seeds” of tumors, according to the company’s website. Although they account for 5 percent or […]